Literature DB >> 24829036

Surgical treatment of microprolactinomas: pros.

Roberto Salvatori1.   

Abstract

Medical therapy with dopaminergic agonists (DAs) has been used for several decades for the treatment of both micro- and macroprolactinomas, without much differentiation between the two conditions. While most cases respond well to DAs in terms of prolactin normalization and control of tumor growth, DAs are often needed for many years, or even for lifetime. Concerns have been raised recently about the possible side effects of long-term use of these medications on the anatomy and function of the heart valves. While macroprolactinomas are rarely surgically curable, pituitary surgery in expert hands is a safe and effective method to permanently cure microprolactinomas, with long-term cure rates around 70 %. In this article, I will review the data on safety of DAs an on the effectiveness and safety of surgery, and I will make an argument that surgery should be offered as a possible therapy to microprolactinoma patients, provided that an experienced pituitary neurosurgeon is available.

Entities:  

Mesh:

Year:  2014        PMID: 24829036     DOI: 10.1007/s12020-014-0281-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  49 in total

1.  Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up.

Authors:  John A Thomson; Christina E Gray; Graham M Teasdale
Journal:  Neurosurgery       Date:  2002-01       Impact factor: 4.654

2.  Cabergoline treatment in acromegaly: cons.

Authors:  Leandro Kasuki; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

3.  Endoscopic transsphenoidal surgery for cushing disease: techniques, outcomes, and predictors of remission.

Authors:  Robert M Starke; Davis L Reames; Ching-Jen Chen; Edward R Laws; John A Jane
Journal:  Neurosurgery       Date:  2013-02       Impact factor: 4.654

4.  Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases.

Authors:  Xin Qu; Min Wang; Guodong Wang; Tao Han; Chengzhi Mou; Lizhang Han; Meng Jiang; Yuanming Qu; Miao Zhang; Qi Pang; Guangming Xu
Journal:  Eur J Endocrinol       Date:  2011-01-20       Impact factor: 6.664

5.  Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases.

Authors:  Sumit Sinha; B S Sharma; A K Mahapatra
Journal:  Neurol India       Date:  2011 Jul-Aug       Impact factor: 2.117

6.  Pituitary surgery: experience from a large network in Central Switzerland.

Authors:  Sven Berkmann; Javier Fandino; Beat Müller; Karl F Kothbauer; Christoph Henzen; Hans Landolt
Journal:  Swiss Med Wkly       Date:  2012-10-01       Impact factor: 2.193

Review 7.  Pituitary centers of excellence.

Authors:  Nancy McLaughlin; Edward R Laws; Nelson M Oyesiku; Laurence Katznelson; Daniel F Kelly
Journal:  Neurosurgery       Date:  2012-11       Impact factor: 4.654

8.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

9.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

10.  Transsphenoidal surgery for microprolactinomas in women: results and prognosis.

Authors:  Arimantas Tamasauskas; Kestutis Sinkunas; Adomas Bunevicius; Andrius Radziunas; Daina Skiriute; Vytenis P Deltuva
Journal:  Acta Neurochir (Wien)       Date:  2012-08-03       Impact factor: 2.216

View more
  7 in total

Review 1.  Prolactinomas, cabergoline, and pregnancy.

Authors:  Andrea Glezer; Marcello D Bronstein
Journal:  Endocrine       Date:  2014-07-02       Impact factor: 3.633

Review 2.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

3.  Surgical Treatment of Cystic Pituitary Prolactin-Secreting Macroadenomas: A Single Center Study of 42 Patients.

Authors:  Xiang Guo; Juan Chen; Zhuo Zhang; Xueyan Wan; Kai Shu; Ting Lei
Journal:  Brain Sci       Date:  2022-05-27

4.  Significance of surgical management for cystic prolactinoma.

Authors:  Toshihiro Ogiwara; Tetsuyoshi Horiuchi; Alhusain Nagm; Tetsuya Goto; Kazuhiro Hongo
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

5.  Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.

Authors:  Christine G Yedinak; Isabelle Cetas; Alp Ozpinar; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2016-07-26       Impact factor: 3.633

Review 6.  Treating prolactinomas with dopamine agonists: always worth the gamble?

Authors:  Sean Noronha; Victoria Stokes; Niki Karavitaki; Ashley Grossman
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

Review 7.  Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis.

Authors:  Jianglong Lu; Lin Cai; Zerui Wu; Weiwei Lin; Jiadong Xu; Zhangzhang Zhu; Chengde Wang; Qun Li; Zhipeng Su
Journal:  Int J Endocrinol       Date:  2021-08-30       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.